title: Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
abstract: BACKGROUND
  The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non-small cell lung cancer (NSCLC) during treatment with erlotinib and its relation to disease progression was investigated.
  
  
  METHODS
  The amount of EGFR-mutant DNA was tested in plasma DNA from patients with advanced NSCLC with allele-specific polymerase chain reaction assays. Blood samples from 23 patients with adenocarcinoma of NSCLC that carried tyrosine kinase inhibitor-sensitizing EGFR mutations were taken immediately before treatment with erlotinib. Additional blood samples were taken at timed intervals until erlotinib treatment was withdrawn.
  
  
  RESULTS
  The amount of plasma DNA with sensitizing EGFR mutations was found to be reduced after the first cycle of erlotinib treatment in 22 of 23 patients (96%). No patients presented with the resistant T790M mutation in the pretreatment sample, but at the time of disease progression the mutation was detected in plasma from 9 patients (39%). The quantitative data from the current study demonstrated that when a T790M mutation emerged in the blood it was accompanied by an increase in the original sensitizing EGFR mutation. When T790M was detected, it was found to be present in all subsequent blood samples from that patient. Most interestingly, the results of the current study demonstrated that monitoring the EGFR mutations in the blood allows for the detection of the T790M mutation up to 344 days before disease progression is clinically evident (range, 15-344 days).
  
  
  CONCLUSIONS
  The results of the current study demonstrated that serial monitoring of EGFR mutations in plasma DNA is feasible and may allow for the early detection of resistance mutations. These results warrant further studies to explore the clinical usefulness of such analysis.
authors.affiliation: Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: Boe S
authors.initials: BS
authors.lastname: Sorensen
authors.forename: Lin
authors.initials: L
authors.lastname: Wu
authors.forename: Wen
authors.initials: W
authors.lastname: Wei
authors.forename: Julie
authors.initials: J
authors.lastname: Tsai
authors.forename: Britta
authors.initials: B
authors.lastname: Weber
authors.forename: Ebba
authors.initials: E
authors.lastname: Nexo
authors.forename: Peter
authors.initials: P
authors.lastname: Meldgaard
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000032:analysis / Q000097:blood*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors
keywords: epidermal growth factor receptor (EGFR) mutations; erlotinib; lung cancer; plasma DNA; resistance
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
references.pmid: 18227510
references.citation: BMC Cancer. 2014 Apr 28;14:294
references.pmid: 24773774
references.citation: N Engl J Med. 2013 Mar 28;368(13):1199-209
references.pmid: 23484797
references.citation: J Thorac Oncol. 2011 Oct;6(10):1639-48
references.pmid: 21921847
references.citation: Nature. 2013 May 2;497(7447):108-12
references.pmid: 23563269
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Clin Cancer Res. 2011 Mar 15;17(6):1616-22
references.pmid: 21135146
references.citation: N Engl J Med. 2005 Feb 24;352(8):786-92
references.pmid: 15728811
references.citation: Nat Med. 2008 Sep;14(9):914-5
references.pmid: 18776881
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168
references.citation: Respiration. 2013;85(2):119-25
references.pmid: 22797485
references.citation: Clin Cancer Res. 1999 Oct;5(10):2689-92
references.pmid: 10537330
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1160-8
references.pmid: 21233402
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: J Thorac Oncol. 2012 Sep;7(9):1369-81
references.pmid: 22858585
references.citation: Cancer Res. 2001 Jun 15;61(12):4675-8
references.pmid: 11406535
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073